0001179110-14-007079.txt : 20140424
0001179110-14-007079.hdr.sgml : 20140424
20140424171139
ACCESSION NUMBER: 0001179110-14-007079
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140422
FILED AS OF DATE: 20140424
DATE AS OF CHANGE: 20140424
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACCELERON PHARMA INC
CENTRAL INDEX KEY: 0001280600
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 128 SYDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-649-9200
MAIL ADDRESS:
STREET 1: 128 SYDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ertel Steven D
CENTRAL INDEX KEY: 0001586752
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36065
FILM NUMBER: 14782400
MAIL ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
edgar.xml
FORM 4 -
X0306
4
2014-04-22
0
0001280600
ACCELERON PHARMA INC
XLRN
0001586752
Ertel Steven D
128 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
SVP & Chief Business Officer
Common Stock
2014-04-22
4
M
0
2500
0.40
A
30156
D
Common Stock
2014-04-22
4
S
0
1800
35.75
D
28356
D
Common Stock
2014-04-22
4
S
0
700
36.17
D
27656
D
Option to Purchase Common Stock
0.40
2014-04-22
4
M
0
2500
0
A
2016-01-18
Common Stock
16875
14375
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2013.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.04 to $36.03, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.10 to $36.33, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
The options of registrants' common stock vested 25% on the first anniversary of the grant and in equal installments quarterly thereafter.
/s/ Kevin F. McLaughlin, as attorney-in-fact for Steven D. Ertel
2014-04-24